Free tool
FAERS Monitor: Smoflipid 20%
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207648 or its brand name (Smoflipid 20%, Fish Oil, Medium Chain Triglycerides, Olive Oil, Soybean Oil). Reports on generic versions are filed under their own applications.
Reports
874
Serious
665
76% of reports
Hospitalization
350
Death reported
105
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia58
- vomiting53
- off label use52
- nausea51
- malaise41
- dyspnoea38
- death36
- intentional product use issue34
- chills31
- fatty acid deficiency31
- hypertriglyceridaemia31
- diarrhoea29
- cholestasis27
- parenteral nutrition associated liver disease25
- product use issue25
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 10 |
| 2015 | 8 |
| 2016 | 34 |
| 2017 | 78 |
| 2018 | 121 |
| 2019 | 98 |
| 2020 | 64 |
| 2021 | 68 |
| 2022 | 60 |
| 2023 | 91 |
| 2024 | 93 |
| 2025 | 75 |
| 2026 | 71 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,285 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fatty acid deficiencySignal | 31 | 14642.0 | 9416.6 | 273,234 |
| parenteral nutrition associated liver diseaseSignal | 25 | 9409.5 | 5955.0 | 162,427 |
| hypertriglyceridaemiaSignal | 31 | 128.1 | 90.6 | 3,765 |
| cholestasisSignal | 27 | 33.9 | 23.4 | 829 |
| intentional product use issueSignal | 34 | 9.3 | 6.7 | 246 |
| chillsSignal | 31 | 6.4 | 4.5 | 136 |
| pyrexiaSignal | 58 | 4.0 | 3.1 | 131 |
| product use issueSignal | 25 | 3.2 | 2.2 | 36 |
| vomitingSignal | 53 | 2.7 | 2.1 | 57 |
| malaiseSignal | 41 | 2.2 | 1.7 | 28 |
| dyspnoea | 38 | 1.6 | 1.2 | 9 |
| nausea | 51 | 1.6 | 1.2 | 10 |
| off label use | 52 | 1.4 | 1.1 | 7 |
| diarrhoea | 29 | 1.1 | 0.8 | 0 |
| death | 36 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.